Safinamide
- Generic Name
- Safinamide
- Brand Names
- Xadago
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19FN2O2
- CAS Number
- 133865-89-1
- Unique Ingredient Identifier
- 90ENL74SIG
- Background
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
- Indication
用于治疗帕金森病
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 227
- Registration Number
- NCT00642889
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Newron Pharmaceuticals SPA
- Target Recruit Count
- 269
- Registration Number
- NCT00643045
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath